Unknown NA INTERVENTIONAL 1-arm NCT01832285

Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients

Effect of Fluvoxamine Augmentation on Cognitive Function , Aggressive Behavior , Clinical Symptoms and mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) in Medicated Schizophrenia Patients

Sponsor: Sha'ar Menashe Mental Health Center

Conditions SCHIZOPHRENIA 1 (Disorder)

Interventions fluvoxamine

Updated 6 times since 2017 Last updated: Apr 22, 2013 Started: Dec 31, 2012 Primary completion: Oct 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01832285, this NA trial focuses on SCHIZOPHRENIA 1 (Disorder) and remains ongoing. Sponsored by Sha'ar Menashe Mental Health Center, it has been updated 6 times since 2012, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Sep 2020 — Jan 2021 [monthly]

Unknown Status NA
Jun 2018 — Sep 2020 [monthly]

Unknown Status NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status NA

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sha'ar Menashe Mental Health Center

Data source: Sha'ar Menashe Mental Health Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hadera, Israel